ClinicalTrials.gg
CompletedNCT03773978JUVE-BASISUpdated Oct 7, 2022Results posted

A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

A Phase 3 interventional study of Baricitinib and Placebo in Juvenile Idiopathic Arthritis, sponsored by Eli Lilly and Company. Completed at 86 sites in 20 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-10-07.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.

Enrollment
Largest of 11
220 · median 58
Started
2018
the only one that year
Phase 3
10 of 12
3 open now
Registered
6th of 12
by date
Lead sponsor
3 of 12
Eli Lilly and Company

Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 10 in phase 3, and was the 6th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Juvenile with a site in Japan, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Keywords

  • Polyarticular JIA
  • Oligoarthritis
  • Juvenile psoriatic arthritis (JPsA)
  • Enthesitis-related juvenile idiopathic arthritis (ERA)
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have had a diagnosis of active JIA (polyarticular, extended oligoarticular, or enthesitis-related juvenile idiopathic arthritis [ERA] including JPsA).
  • Participants must have had an inadequate response to at least one conventional or biologic disease-modifying antirheumatic drug (DMARD).

Exclusion criteria

Exclusion Criteria:

  • Participants must not have systemic JIA, with or without active systemic features.
  • Participants must not have persistent oligoarticular arthritis.
  • Participants must not have been previously treated with a Janus kinase (JAK) inhibitor.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Experimental
    Baricitinib

    Baricitinib was administered QD (once daily) as a 4-mg oral tablet for adolescent participants (12 to \<18 years of age) and children ≥9 years of age; and 2 mg for children \<9 years of age. Participants \<6 years of age received an oral suspension. Participants ≥6 to \<12 years old had the option of receiving an oral suspension. Participants \>12 years old were supplied tablets. The oral suspension dose was administered as 4-mg, 2-mg, 1-mg, and 0.5-mg as needed.

    Drug: Baricitinib

  • Placebo comparator
    Placebo

    Placebo matched to baricitinib was administered to participants during the DBW period.

    Drug: Placebo

Interventions

  • Administered orally.

    Also known as: LY3009104

  • DrugPlacebo

    Administered orally.

06

What researchers measure

Primary outcomes

  1. Time to Disease Flare

    A disease flare is defined as a worsening of 30% or more in at least three of the six core Paediatric American College of Rheumatology (PedACR) criteria for juvenile rheumatoid arthritis (JIA) and an improvement of 30% or more in no more than one of the criteria. The six PedACR criteria are: 1) the number of active joints, 2) the number of joints with limited range of motion, 3) physician's global assessment of disease activity, 4) parent's global assessment of the participant's overall well-being, 5) physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ) and 6) acute-phase reactant (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]), the ESR measure is only used as an acute phase reactant in the core criteria.

    Time frame: Week 12 to Week 44

Secondary outcomes

  1. Percentage of Participants Achieving PedACR30 Responder Index

    The PedACR30 response is defined as at least 30% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \>30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle visual analogue scale \[VAS\]), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  2. Percentage of Participants Achieving PedACR50 Responder Index

    The PedACR50 response is defined as at least 50% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  3. Percentage of Participants Achieving PedACR70 Responder Index

    The PedACR70 response is defined as at least 70% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  4. Percentage of Participants Achieving PedACR90 Responder Index

    The PedACR90 response is defined as at least 90% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  5. Percentage of Participants Achieving PedACR100 Responder Index

    The PedACR100 response is defined as at least 100% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  6. Percentage of Participants With Inactive Disease

    Inactive disease is defined as the presence of all of the following: 1. No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS) - 27 score, 2. No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3. No active uveitis as assessed by the investigator, 4. Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5. Physician's Global Assessment of Disease Activity indicating no active disease (Score ranges are 0 to 100 and best possible score on scale is 0) and 6. Duration of morning stiffness ≤15 minutes.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  7. Percentage of Participants With Minimal Disease Activity

    Minimal disease activity is calculated based on the scores from the 1. Physician's Global Assessment of Disease Activity 2. Parent's Global Assessment of Well-Being and 3. the number of swollen joints. If the physician's global assessment of disease activity is ≤3.5 (score range: 0-100), the parent's global rating of patient's overall well-being is ≤2.5 (score range: 0-100), and the swollen joint count is ≤1 (score range: 0-73), then the participant reaches minimal disease activity. if not, minimal disease activity is not reached.

    Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44

  8. Percentage of Participants in Remission

    Remission is defined as inactive disease for at least 24 consecutive weeks. Inactive disease is defined as the presence of all of the following: 1) No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS)-27 score, 2) No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3) No active uveitis as assessed by the investigator, 4) Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5) Physician's Global Assessment of Disease Activity indicating no active disease (best possible score on scale \[0\]) and 6) Duration of morning stiffness ≤15 minutes.

    Time frame: Week 28, 32, 36, 40 and 44

  9. Change From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score

    The JADAS-27 score is based on 4 components: 1) Physician's global assessment of disease activity on a 0-100 mm VAS, 2) Parent's global assessment of overall well-being on a 0-100 mm VAS, 3) normalized ESR and 4) number of joints (maximum of 27) with active arthritis (cervical spine, elbows, wrists, metacarpophalangeal joints \[from first to third\], proximal interphalangeal joints, hips, knees, and ankles). The scores for the each of the first 3 components range from 0 -10; the score for the final component ranges from 0-27. The overall JADAS-27 score is sum of the 4 components and it ranges from 0-57. A higher score indicates more disease activity. Least square (LS) mean was calculated using Analysis of covariance (ANCOVA) model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

    Time frame: Baseline, Week 44

  10. Change From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item

    CHAQ assesses the health status and physical function of children with juvenile arthritis over the past week. The CHAQ consists of a Disability Index and a Discomfort Index. The disability index consisted of 30 items grouped into the following 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3 (0 = no difficulty; 1 = some difficulty; 2 = much difficulty and 3 = unable to do or not applicable). The scores of 8 domains were averaged to calculate the CHAQ-Disability Index total score. A higher score indicates worse physical function. The discomfort index consisted of Parent's Global Assessment of Well-Being and pain assessment due to illness. The intensity of pain is scored on a VAS scale ranging from 0-100 mm, with zero referring to "no pain" and 100 referring to "very severe pain". A higher score indicates a worse outcome.

    Time frame: Baseline, Week 44

  11. Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

    PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk and legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

    Time frame: Baseline, Week 44

  12. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index

    The SPARCC enthesitis is an index used to measure the severity of enthesitis (sites at which tendons and ligaments attach to bones). The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

    Time frame: Baseline, Week 44

  13. Change From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index

    The JSpADA index is used to evaluate the disease activity of juvenile spondyloarthritis. The JSpADA index scores will be determined by following 8 components: active joint count, active enthesitis count, pain over the past week, CRP level related to juvenile spondyloarthritis activity, morning stiffness greater than 15 minutes, clinical sacroiliitis, uveitis and back mobility. All items are transformed to values of 0, 0.5, or 1, and the total score ranges from 0 to 8, where higher scores indicate more disease activity. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

    Time frame: Baseline, Week 44

  14. Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)

    Maximum Plasma Baricitinib Concentration at Steady-State

    Time frame: For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)

  15. PK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss)

    Area under the concentration-time curve of Baricitinib during a dosing interval at steady state.

    Time frame: For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)

  16. Change From Baseline in Immunoglobulin Levels

    Change from baseline in Serum Immunoglobulin A, Serum Immunoglobulin G and Serum Immunoglobulin M levels at week 12 are presented.

    Time frame: Baseline, Week 12

  17. Number of Participants With Change of Immunoglobulin G (IgG) Titers

    Number of participants with change of IgG titers eligible for tetanus / diphtheria / acellular pertussis (tDaP) vaccine and pneumococcal conjugate are presented. Participants who were immunized with tDaP or pneumococcal conjugate vaccine had their IgG antibody titers to the antigens evaluated preimmunization and at 4 and 12 weeks postimmunization. A primary immune response was assessed in participants who had never received tDaP or pneumococcal conjugate vaccines previously and secondary/booster responses were assessed if the participants had previously received the vaccines. For pneumococcal conjugate vaccine, number of participants with \>= 2-fold increase from baseline in \>=6 pneumococcal serotypes at week 4 and 12 is presented. For tDaP vaccine, number of participants with \>= 4-fold increase from baseline in participants with baseline titer \>=0.1 IU/mL at week 4 and 12 is presented.

    Time frame: Pre-Vaccination to 4 and 12 Weeks Post-Vaccination

  18. Number of Participants With Product Acceptability and Palatability Assessment

    The questionnaire for product acceptability and palatability assessed the participants ability to swallow the tablet, experience relating to the taste, smell and ease of administering and taking the suspension. The questionnaire contained following Questions: Question 1) How did you (your child) like the taste of the medicine? Question 2) How did you (your child) like the smell of the medicine? Question 3) How easy was it for you (your child) to take the medicine today? Question 4) How easy was it for you to use the oral syringe to give your child the dose today? and Question 5) How easy was it for you (your child) to swallow the medicine today? Responses: Liked Very Much, Liked, Neither Liked nor Disliked, Disliked, Disliked Very Much, Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as "Question Number-Response-Time point".

    Time frame: Baseline and week 12

07

Results

Posted Oct 7, 2022

Participant flow

Overall, 220 participants were enrolled: 29 started with the Pharmacokinetics (PK)/Safety period (2 weeks), and one participant was discontinued due to protocol deviation. 191 participants entered into the Open-label lead-in period (OLLI) period, and during week 2, 28 participants from the PK/Safety population entered into the OLLI period.

PK/Safety and OLLI Period
Participant flow — PK/Safety and OLLI Period
MilestoneBaricitinibPlacebo
Started2200
Pk/safety period290
Olli period2190
Received at least one dose of study drug2200
Completed1630
Not completed570
Withdrew: Adverse event10
Withdrew: Failure to meet randomization criteria390
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject30
Withdrew: Due to epidemic or pandemic60
Withdrew: Unexplainable flare disease10
Withdrew: Protocol violation40
Withdrew: Participant transitioned to jahx10
Withdrew: Investigational product was not delivered to the site10
DBW Period
Participant flow — DBW Period
MilestoneBaricitinibPlacebo
Started8281
Completed5632
Not completed2649
Withdrew: Adverse event22
Withdrew: Failure to meet continuation criteria1640
Withdrew: Withdrawal by subject21
Withdrew: Due to epidemic or pandemic56
Withdrew: Study team decision10

Outcome measures

PrimaryTime to Disease Flare

A disease flare is defined as a worsening of 30% or more in at least three of the six core Paediatric American College of Rheumatology (PedACR) criteria for juvenile rheumatoid arthritis (JIA) and an improvement of 30% or more in no more than one of the criteria. The six PedACR criteria are: 1) the number of active joints, 2) the number of joints with limited range of motion, 3) physician's global assessment of disease activity, 4) parent's global assessment of the participant's overall well-being, 5) physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ) and 6) acute-phase reactant (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]), the ESR measure is only used as an acute phase reactant in the core criteria.

Time frame:
Week 12 to Week 44
Reported as:
Median · Weeks
Time to Disease Flare
WeeksBaricitinibPlacebo
Time to Disease FlareNA (NA to NA)27.14 (15.29 to NA)
Statistical analysis
  • Baricitinib vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 0.241 · 95% CI 0.128 to 0.453
SecondaryPercentage of Participants Achieving PedACR30 Responder Index

The PedACR30 response is defined as at least 30% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \>30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle visual analogue scale \[VAS\]), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PedACR30 Responder Index
Percentage of participantsBaricitinibPlacebo
At week 1692.7 (87 to 98.3)81.5 (73 to 89.9)
At week 2087.8 (80.7 to 94.9)64.2 (53.8 to 74.6)
At week 2485.4 (77.7 to 93.0)55.6 (44.7 to 66.4)
At week 2878 (69.1 to 87)51.9 (41 to 62.7)
At week 3274.4 (64.9 to 83.8)49.4 (38.5 to 60.3)
At week 3672.0 (62.2 to 81.7)44.4 (33.6 to 55.3)
At week 4069.5 (59.5 to 79.5)38.3 (27.7 to 48.9)
At week 4467.1 (56.9 to 77.2)38.3 (27.7 to 48.9)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.052 · Odds ratio (or): 2.72 · 95% CI 0.99 to 7.46
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.64 · 95% CI 1.60 to 8.28
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.34 · 95% CI 2.00 to 9.41
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.001 · Odds ratio (or): 3.37 · 95% CI 1.62 to 7.01
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.00 · 95% CI 1.48 to 6.07
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.25 · 95% CI 1.62 to 6.52
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.70 · 95% CI 1.85 to 7.41
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.27 · 95% CI 1.65 to 6.50
SecondaryPercentage of Participants Achieving PedACR50 Responder Index

The PedACR50 response is defined as at least 50% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PedACR50 Responder Index
Percentage of participantsBaricitinibPlacebo
At week 1679.3 (70.5 to 88)75.3 (65.9 to 84.7)
At week 2081.7 (73.3 to 90.1)58 (47.3 to 68.8)
At week 2481.7 (73.3 to 90.1)49.4 (38.5 to 60.3)
At week 2875.6 (66.3 to 84.9)50.6 (39.7 to 61.5)
At week 3272 (62.2 to 81.7)46.9 (36 to 57.8)
At week 3668.3 (58.2 to 78.4)43.2 (32.4 to 54)
At week 4068.3 (58.2 to 78.4)38.3 (27.7 to 48.9)
At week 4463.4 (53 to 73.8)37 (26.5 to 47.6)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.568 · Odds ratio (or): 1.25 · 95% CI 0.59 to 2.65
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.004 · Odds ratio (or): 2.92 · 95% CI 1.40 to 6.09
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 4.38 · 95% CI 2.10 to 9.15
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 3.09 · 95% CI 1.51 to 6.32
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 2.99 · 95% CI 1.47 to 6.11
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 2.84 · 95% CI 1.44 to 5.60
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.49 · 95% CI 1.74 to 6.97
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.87 · 95% CI 1.46 to 5.66
SecondaryPercentage of Participants Achieving PedACR70 Responder Index

The PedACR70 response is defined as at least 70% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PedACR70 Responder Index
Percentage of participantsBaricitinibPlacebo
At week 1654.9 (44.1 to 65.6)54.3 (43.5 to 65.2)
At week 2068.3 (58.2 to 78.4)45.7 (34.8 to 56.5)
At week 2459.8 (49.1 to 70.4)37.0 (26.5 to 47.6)
At week 2867.1 (56.9 to 77.2)39.5 (28.9 to 50.2)
At week 3257.3 (46.6 to 68)35.8 (25.4 to 46.2)
At week 3661 (50.4 to 71.5)35.8 (25.4 to 46.2)
At week 4057.3 (46.6 to 68)30.9 (20.8 to 40.9)
At week 4453.7 (42.9 to 64.5)35.8 (25.4 to 46.2)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.972 · Odds ratio (or): 0.99 · 95% CI 0.52 to 1.87
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.008 · Odds ratio (or): 2.47 · 95% CI 1.27 to 4.81
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.005 · Odds ratio (or): 2.57 · 95% CI 1.33 to 4.97
  • Baricitinib vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.06 · 95% CI 1.57 to 5.94
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.009 · Odds ratio (or): 2.42 · 95% CI 1.25 to 4.71
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.003 · Odds ratio (or): 2.80 · 95% CI 1.43 to 5.47
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.002 · Odds ratio (or): 2.93 · 95% CI 1.47 to 5.83
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.052 · Odds ratio (or): 1.93 · 95% CI 0.99 to 3.74
SecondaryPercentage of Participants Achieving PedACR90 Responder Index

The PedACR90 response is defined as at least 90% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PedACR90 Responder Index
Percentage of participantsBaricitinibPlacebo
At week 1629.3 (19.4 to 39.1)23.5 (14.2 to 32.7)
At week 2042.7 (32 to 53.4)24.7 (15.3 to 34.1)
At week 2437.8 (27.3 to 48.3)21 (12.1 to 29.9)
At week 2842.7 (32 to 53.4)25.9 (16.4 to 35.5)
At week 3243.9 (33.2 to 54.6)27.2 (17.5 to 36.8)
At week 3639 (28.5 to 49.6)27.2 (17.5 to 36.8)
At week 4040.2 (29.6 to 50.9)23.5 (14.2 to 32.7)
At week 4442.7 (32 to 53.4)23.5 (14.2 to 32.7)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.409 · Odds ratio (or): 1.35 · 95% CI 0.66 to 2.75
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.030 · Odds ratio (or): 2.13 · 95% CI 1.07 to 4.23
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.022 · Odds ratio (or): 2.36 · 95% CI 1.13 to 4.92
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.040 · Odds ratio (or): 2.05 · 95% CI 1.03 to 4.08
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.032 · Odds ratio (or): 2.13 · 95% CI 1.07 to 4.24
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.132 · Odds ratio (or): 1.71 · 95% CI 0.85 to 3.42
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.050 · Odds ratio (or): 2.02 · 95% CI 1.00 to 4.10
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.019 · Odds ratio (or): 2.32 · 95% CI 1.15 to 4.71
SecondaryPercentage of Participants Achieving PedACR100 Responder Index

The PedACR100 response is defined as at least 100% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PedACR100 Responder Index
Percentage of participantsBaricitinibPlacebo
At week 1614.6 (7 to 22.3)17.3 (9 to 25.5)
At week 2024.4 (15.1 to 33.7)19.8 (11.1 to 28.4)
At week 2418.3 (9.9 to 26.7)16 (8.1 to 24)
At week 2826.8 (17.2 to 36.4)19.8 (11.1 to 28.4)
At week 3228 (18.3 to 37.8)21 (12.1 to 29.9)
At week 3629.3 (19.4 to 39.1)21 (12.1 to 29.9)
At week 4029.3 (19.4 to 39.1)17.3 (9 to 25.5)
At week 4429.3 (19.4 to 39.1)16 (8.1 to 24)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.620 · Odds ratio (or): 0.80 · 95% CI 0.33 to 1.92
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.492 · Odds ratio (or): 1.30 · 95% CI 0.61 to 2.78
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.715 · Odds ratio (or): 1.17 · 95% CI 0.50 to 2.75
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.384 · Odds ratio (or): 1.40 · 95% CI 0.66 to 2.99
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.311 · Odds ratio (or): 1.47 · 95% CI 0.70 to 3.10
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.231 · Odds ratio (or): 1.58 · 95% CI 0.75 to 3.34
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.129 · Odds ratio (or): 1.82 · 95% CI 0.84 to 3.95
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.043 · Odds ratio (or): 2.23 · 95% CI 1.02 to 4.84
SecondaryPercentage of Participants With Inactive Disease

Inactive disease is defined as the presence of all of the following: 1. No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS) - 27 score, 2. No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3. No active uveitis as assessed by the investigator, 4. Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5. Physician's Global Assessment of Disease Activity indicating no active disease (Score ranges are 0 to 100 and best possible score on scale is 0) and 6. Duration of morning stiffness ≤15 minutes.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants With Inactive Disease
Percentage of participantsBaricitinibPlacebo
At week 1612.2 (5.1 to 19.3)11.1 (4.3 to 18.0)
At week 2013.4 (6.0 to 20.8)17.3 (9 to 25.5)
At week 2417.1 (8.9 to 25.2)17.3 (9.0 to 25.5)
At week 2820.7 (12.0 to 29.5)13.6 (6.1 to 21.0)
At week 3222.0 (13.0 to 30.9)13.6 (6.1 to 21.0)
At week 3623.2 (14.0 to 32.3)16.0 (8.1 to 24)
At week 4020.7 (12.0 to 29.5)12.3 (5.2 to 19.5)
At week 4423.2 (14.0 to 32.3)13.6 (6.1 to 21.0)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.853 · Odds ratio (or): 1.10 · 95% CI 0.40 to 2.98
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.432 · Odds ratio (or): 0.70 · 95% CI 0.29 to 1.71
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.960 · Odds ratio (or): 0.98 · 95% CI 0.41 to 2.31
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.215 · Odds ratio (or): 1.71 · 95% CI 0.73 to 4.01
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.173 · Odds ratio (or): 1.80 · 95% CI 0.77 to 4.22
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.367 · Odds ratio (or): 1.46 · 95% CI 0.64 to 3.33
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.162 · Odds ratio (or): 1.90 · 95% CI 0.77 to 4.67
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.113 · Odds ratio (or): 1.96 · 95% CI 0.85 to 4.50
SecondaryPercentage of Participants With Minimal Disease Activity

Minimal disease activity is calculated based on the scores from the 1. Physician's Global Assessment of Disease Activity 2. Parent's Global Assessment of Well-Being and 3. the number of swollen joints. If the physician's global assessment of disease activity is ≤3.5 (score range: 0-100), the parent's global rating of patient's overall well-being is ≤2.5 (score range: 0-100), and the swollen joint count is ≤1 (score range: 0-73), then the participant reaches minimal disease activity. if not, minimal disease activity is not reached.

Time frame:
Week 16, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants With Minimal Disease Activity
Percentage of participantsBaricitinibPlacebo
At week 1636.6 (26.2 to 47)40.7 (30 to 51.4)
At week 2046.3 (35.5 to 57.1)33.3 (23.1 to 43.6)
At week 2443.9 (33.2 to 54.6)34.6 (24.2 to 44.9)
At week 2845.1 (34.4 to 55.9)33.3 (23.1 to 43.6)
At week 3243.9 (33.2 to 54.6)32.1 (21.9 to 42.3)
At week 3640.2 (29.6 to 50.9)33.3 (23.1 to 43.6)
At week 4043.9 (33.2 to 54.6)32.1 (21.9 to 42.3)
At week 4443.9 (33.2 to 54.6)27.2 (17.5 to 36.8)
Statistical analysis
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.511 · Odds ratio (or): 0.80 · 95% CI 0.42 to 1.55
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.145 · Odds ratio (or): 1.64 · 95% CI 0.84 to 3.20
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.349 · Odds ratio (or): 1.38 · 95% CI 0.70 to 2.72
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.167 · Odds ratio (or): 1.63 · 95% CI 0.82 to 3.25
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.212 · Odds ratio (or): 1.55 · 95% CI 0.78 to 3.07
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.577 · Odds ratio (or): 1.21 · 95% CI 0.62 to 2.39
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.225 · Odds ratio (or): 1.51 · 95% CI 0.78 to 2.95
  • Baricitinib vs Placebo · Regression, Logistic · p = 0.055 · Odds ratio (or): 1.96 · 95% CI 0.98 to 3.90
SecondaryPercentage of Participants in Remission

Remission is defined as inactive disease for at least 24 consecutive weeks. Inactive disease is defined as the presence of all of the following: 1) No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS)-27 score, 2) No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3) No active uveitis as assessed by the investigator, 4) Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5) Physician's Global Assessment of Disease Activity indicating no active disease (best possible score on scale \[0\]) and 6) Duration of morning stiffness ≤15 minutes.

Time frame:
Week 28, 32, 36, 40 and 44
Reported as:
Number · Percentage of participants
Percentage of Participants in Remission
Percentage of participantsBaricitinibPlacebo
At week 280 (0 to 0)0 (0 to 0)
At week 320 (0 to 0)1.2 (0 to 3.6)
At week 361.2 (0 to 3.6)4.9 (0.2 to 9.7)
At week 402.4 (0 to 5.8)3.7 (0 to 7.8)
At week 443.7 (0 to 7.7)3.7 (0 to 7.8)
SecondaryChange From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score

The JADAS-27 score is based on 4 components: 1) Physician's global assessment of disease activity on a 0-100 mm VAS, 2) Parent's global assessment of overall well-being on a 0-100 mm VAS, 3) normalized ESR and 4) number of joints (maximum of 27) with active arthritis (cervical spine, elbows, wrists, metacarpophalangeal joints \[from first to third\], proximal interphalangeal joints, hips, knees, and ankles). The scores for the each of the first 3 components range from 0 -10; the score for the final component ranges from 0-27. The overall JADAS-27 score is sum of the 4 components and it ranges from 0-57. A higher score indicates more disease activity. Least square (LS) mean was calculated using Analysis of covariance (ANCOVA) model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

Time frame:
Baseline, Week 44
Reported as:
Least squares mean · score on a scale
Change From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score
score on a scaleBaricitinibPlacebo
Change From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score-14.24 ± 1.006-9.91 ± 1.013
Statistical analysis
  • Baricitinib vs Placebo · ANCOVA · p = 0.001 · Ls mean difference: -4.33 · 95% CI -6.95 to -1.70
SecondaryChange From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item

CHAQ assesses the health status and physical function of children with juvenile arthritis over the past week. The CHAQ consists of a Disability Index and a Discomfort Index. The disability index consisted of 30 items grouped into the following 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3 (0 = no difficulty; 1 = some difficulty; 2 = much difficulty and 3 = unable to do or not applicable). The scores of 8 domains were averaged to calculate the CHAQ-Disability Index total score. A higher score indicates worse physical function. The discomfort index consisted of Parent's Global Assessment of Well-Being and pain assessment due to illness. The intensity of pain is scored on a VAS scale ranging from 0-100 mm, with zero referring to "no pain" and 100 referring to "very severe pain". A higher score indicates a worse outcome.

Time frame:
Baseline, Week 44
Reported as:
Least squares mean · score on a scale
Change From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item
score on a scaleBaricitinibPlacebo
Change From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item-29.65 ± 3.276-16.68 ± 3.202
Statistical analysis
  • Baricitinib vs Placebo · ANCOVA · p = 0.003 · Ls mean difference: -12.97 · 95% CI -21.39 to -4.55
SecondaryChange From Baseline in Psoriasis Area and Severity Index (PASI) Score

PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk and legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

Time frame:
Baseline, Week 44
Reported as:
Least squares mean · score on a scale
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
score on a scaleBaricitinibPlacebo
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score-1.14 ± 0.291-0.79 ± 0.354
Statistical analysis
  • Baricitinib vs Placebo · ANCOVA · p = 0.574 · Ls mean difference: -0.35 · 95% CI -2.62 to 1.91
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index

The SPARCC enthesitis is an index used to measure the severity of enthesitis (sites at which tendons and ligaments attach to bones). The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

Time frame:
Baseline, Week 44
Reported as:
Least squares mean · score on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index
score on a scaleBaricitinibPlacebo
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index-1.51 ± 0.276-1.95 ± 0.241
Statistical analysis
  • Baricitinib vs Placebo · ANCOVA · p = 0.208 · Ls mean difference: 0.45 · 95% CI -0.26 to 1.15
SecondaryChange From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index

The JSpADA index is used to evaluate the disease activity of juvenile spondyloarthritis. The JSpADA index scores will be determined by following 8 components: active joint count, active enthesitis count, pain over the past week, CRP level related to juvenile spondyloarthritis activity, morning stiffness greater than 15 minutes, clinical sacroiliitis, uveitis and back mobility. All items are transformed to values of 0, 0.5, or 1, and the total score ranges from 0 to 8, where higher scores indicate more disease activity. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.

Time frame:
Baseline, Week 44
Reported as:
Least squares mean · score on a scale
Change From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index
score on a scaleBaricitinibPlacebo
Change From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index-2.56 ± 0.347-1.47 ± 0.296
Statistical analysis
  • Baricitinib vs Placebo · ANCOVA · p = 0.019 · Ls mean difference: -1.08 · 95% CI -1.98 to -0.19
SecondaryPharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)

Maximum Plasma Baricitinib Concentration at Steady-State

Time frame:
For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)
Nanograms per milliliter (ng/mL)12 to <18 Years 4-mg QD9 to <12 Years 4-mg QD6 to <9 Years 2-mg QD2 to <6 Years 2-mg QD
Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)57.7 ± 2879 ± 3356.8 ± 2287.4 ± 38
SecondaryPK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss)

Area under the concentration-time curve of Baricitinib during a dosing interval at steady state.

Time frame:
For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)
Reported as:
Geometric mean · hour*nanogram/millilitre (h*ng/mL)
PK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss)
hour*nanogram/millilitre (h*ng/mL)12 to <18 Years 4-mg QD9 to <12 Years 4-mg QD6 to <9 Years 2-mg QD2 to <6 Years 2-mg QD
PK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss)386 ± 45500 ± 57254 ± 27410 ± 57
SecondaryChange From Baseline in Immunoglobulin Levels

Change from baseline in Serum Immunoglobulin A, Serum Immunoglobulin G and Serum Immunoglobulin M levels at week 12 are presented.

Time frame:
Baseline, Week 12
Reported as:
Mean · Milligrams per decilitre (mg/dL)
Change From Baseline in Immunoglobulin Levels
Milligrams per decilitre (mg/dL)Baricitinib
Serum Immunoglobulin A-15.98 ± 39.501
Serum Immunoglobulin G-81.46 ± 209.549
Serum Immunoglobulin M-9.86 ± 26.680
SecondaryNumber of Participants With Change of Immunoglobulin G (IgG) Titers

Number of participants with change of IgG titers eligible for tetanus / diphtheria / acellular pertussis (tDaP) vaccine and pneumococcal conjugate are presented. Participants who were immunized with tDaP or pneumococcal conjugate vaccine had their IgG antibody titers to the antigens evaluated preimmunization and at 4 and 12 weeks postimmunization. A primary immune response was assessed in participants who had never received tDaP or pneumococcal conjugate vaccines previously and secondary/booster responses were assessed if the participants had previously received the vaccines. For pneumococcal conjugate vaccine, number of participants with \>= 2-fold increase from baseline in \>=6 pneumococcal serotypes at week 4 and 12 is presented. For tDaP vaccine, number of participants with \>= 4-fold increase from baseline in participants with baseline titer \>=0.1 IU/mL at week 4 and 12 is presented.

Time frame:
Pre-Vaccination to 4 and 12 Weeks Post-Vaccination
Reported as:
Number · participants
Number of Participants With Change of Immunoglobulin G (IgG) Titers
participantsBaricitinib
Tetanus toxoid containing vaccine at week 42
Tetanus toxoid containing vaccine at week 122
Diphtheria toxoid containing vaccine at week 42
Diphtheria toxoid containing vaccine at week 121
Pertussis toxin containing vaccine at week 42
Pertussis toxin containing vaccine at week 122
pneumococcal conjugate vaccine at week 43
pneumococcal conjugate vaccine at week 122
SecondaryNumber of Participants With Product Acceptability and Palatability Assessment

The questionnaire for product acceptability and palatability assessed the participants ability to swallow the tablet, experience relating to the taste, smell and ease of administering and taking the suspension. The questionnaire contained following Questions: Question 1) How did you (your child) like the taste of the medicine? Question 2) How did you (your child) like the smell of the medicine? Question 3) How easy was it for you (your child) to take the medicine today? Question 4) How easy was it for you to use the oral syringe to give your child the dose today? and Question 5) How easy was it for you (your child) to swallow the medicine today? Responses: Liked Very Much, Liked, Neither Liked nor Disliked, Disliked, Disliked Very Much, Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as "Question Number-Response-Time point".

Time frame:
Baseline and week 12
Reported as:
Number · participants
Number of Participants With Product Acceptability and Palatability Assessment
participantsBaricitinib
Question 1- Liked Very Much: Baseline2
Question 1- Liked Very Much: Week 126
Question 1- Liked: Baseline8
Question 1- Liked: Week 122
Question 1- Neither Liked nor Disliked: Baseline3
Question 1- Neither Liked nor Disliked: Week 121
Question 1- Disliked: Baseline0
Question 1- Disliked: Week 121
Question 1- Disliked Very Much: Baseline0
Question 1- Disliked Very Much: Week 120
Question 2- Liked Very Much: Baseline3
Question 2- Liked Very Much: Week 122
Question 2- Liked: Baseline7
Question 2- Liked: Week 124
Question 2- Neither Liked nor Disliked: Baseline3
Question 2- Neither Liked nor Disliked: Week 122
Question 2- Disliked: Baseline0
Question 2- Disliked: Week 121
Question 2- Disliked Very Much: Baseline0
Question 2- Disliked Very Much: Week 121
Question 3- Very Easy: Baseline8
Question 3- Very Easy: Week 127
Question 3- Easy: Baseline3
Question 3- Easy: Week 122
Question 3- Neither Easy nor Hard: Baseline1
Question 3- Neither Easy nor Hard: Week 120
Question 3- Difficult (or Hard): Baseline0
Question 3- Difficult (or Hard): Week 121
Question 3- Very Difficult (or Hard): Baseline1
Question 3- Very Difficult (or Hard): Week 120
Question 4- Very Easy: Baseline5
Question 4- Very Easy: Week 128
Question 4- Easy: Baseline6
Question 4- Easy: Week 122
Question 4- Neither Easy nor Hard: Baseline0
Question 4- Neither Easy nor Hard: Week 120
Question 4- Difficult (or Hard): Baseline0
Question 4- Difficult (or Hard): Week 120
Question 4- Very Difficult (or Hard): Baseline0
Question 4- Very Difficult (or Hard): Week 120
Question 5- Very Easy: Baseline146
Question 5- Very Easy: Week 12120
Question 5- Easy: Baseline39
Question 5- Easy: Week 1234
Question 5- Neither Easy nor Hard: Baseline14
Question 5- Neither Easy nor Hard: Week 125
Question 5- Difficult (or Hard): Baseline3
Question 5- Difficult (or Hard): Week 120
Question 5- Very Difficult (or Hard): Baseline1
Question 5- Very Difficult (or Hard): Week 120

Adverse events

Collected over Baseline through Follow-up (Up To 341 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib PK and OLLI0/220 (0%)6/220 (2.7%)48/220 (21.8%)
Placebo DBW0/81 (0%)3/81 (3.7%)10/81 (12.3%)
Baricitinib DBW0/82 (0%)4/82 (4.9%)26/82 (31.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventBaricitinib PK and OLLIPlacebo DBWBaricitinib DBW
Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders1/2201/810/82
Suicide attemptPsychiatric disorders0/2201/810/82
BronchospasmRespiratory, thoracic and mediastinal disorders0/2201/810/82
Covid-19Infections and infestations0/2200/811/82
GastroenteritisInfections and infestations0/2200/811/82
HeadacheNervous system disorders0/2200/811/82
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2200/811/82
Decreased appetiteMetabolism and nutrition disorders1/2200/810/82
ArthralgiaMusculoskeletal and connective tissue disorders1/2200/810/82
Joint destructionMusculoskeletal and connective tissue disorders1/2200/810/82
Most frequent other events
Most frequent other events
EventBaricitinib PK and OLLIPlacebo DBWBaricitinib DBW
Upper respiratory tract infectionInfections and infestations11/2201/819/82
HeadacheNervous system disorders14/2203/818/82
NasopharyngitisInfections and infestations19/2203/816/82
ArthralgiaMusculoskeletal and connective tissue disorders11/2203/816/82
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/2201/815/82

Baseline characteristics

Baseline analysis Population includes all randomized participants.

Age, Customized
Age, Customized(Participants)Baricitinib
Age — >=2 to <6 years6
Age — >=6 to <9 years9
Age — >=9 to <12 years30
Age — >=12 to <18 years175
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib
Female152
Male68
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib
Hispanic or Latino43
Not Hispanic or Latino133
Unknown or Not Reported44
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib
American Indian or Alaska Native7
Asian48
Native Hawaiian or Other Pacific Islander0
Black or African American5
White152
More than one race2
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(Participants)Baricitinib
Argentina20
Czechia12
Japan25
United Kingdom11
India6
Spain14
Russia8
Austria2
Turkey3
Belgium7
China18
Brazil2
Poland7
Denmark1
Italy11
Mexico21
Israel15
France10
Australia1
Germany26
08

Study locations

86 sites
  • Instituto CAICI SRL
    Rosario, Santa Fe 2000, Argentina
  • Centro Medico Privado de Reumatologia
    SAN M. DE Tucuman, Tucumán T4000AXL, Argentina
  • Hospital General de Niños Dr. Pedro de Elizalde
    Buenos Aires, C1270AAN, Argentina
  • The Sydney Children's Hospitals Network
    Westmead, New South Wales 2145, Australia
  • Royal Childrens Hospital Melbourne
    Parkville, Victoria 3050, Australia
  • Perth Children's Hospital
    Nedlands, Western Australia 6009, Australia
  • LKH Bregenz
    Bregenz, Vorarlberg 6900, Austria
  • AKH
    Wien, 1090, Austria
  • UCL- Saint Luc
    Brussels, Brussels-Capital 1200, Belgium
  • UZ Gent-Reuma
    Gent, East Flanders 9000, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • CMIP - Centro Mineiro de Pesquisa
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Faculdade de Medicina de Botucatu
    Botucatu, Sao Paulo 18618-970, Brazil
  • Faculdade de Ciências Médicas - UNICAMP
    Campinas, Sao Paulo 13083-887, Brazil
  • Universidade Federal de São Paulo - Escola Paulista de Medicina
    São Paulo, 04038-001, Brazil
  • Children's hospital of Nanjing
    Nanjing, Jiangsu 210008, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, Tianjin City 200041, China
  • Capitol Institute of Pediatrics Children'S Hospital
    Beijing, 100020, China
  • Beijing Children's hospital, Capital Medical University
    Beijing, 100045, China
  • Children's Hospital of Soochow University
    Suzhou, 215025, China
  • Centrum detske revmatologie VFN, Klinika detskeho a dorostoveho lekarstvi 1.LFUK a VFN v Praze
    Prague, 121 08, Czechia
  • Fakultni Nemocnice v Motole
    Praha 5, 15006, Czechia
  • Paediatric rheumatology Unit
    København Ø, 2100, Denmark
  • Center for Børnereumatologi. Børn og Unge, Århus Universitetshospital
    Århus N, 8200, Denmark
  • Hospices Civils de Lyon - Hôpital Femme Mère Enfant
    Bron, 69500, France
  • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre
    Le Kremlin Bicetre, 94270, France
  • Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau
    Nîmes, 30029, France
  • GH Necker - Enfants Malades
    Paris Cedex 15, 75743, France
  • CHU la Miletrie
    Poitiers, 86000, France
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • Asklepios Klinik Sankt Augustin
    Saint Augustin, Nordrhein-Westfalen 53757, Germany
  • HELIOS Klinikum Berlin-Buch
    Berlin, 13125, Germany
  • Charité Universitätsmedizin Berlin Campus Buch
    Berlin, 13353, Germany
  • Schön Klinik Hamburg Eilbek
    Hamburg, 22081, Germany
  • Sri Ramachandra MedicaL College & Research Institute
    Porur, Chennai 600116, India
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110060, India
  • Christian Medical College Vellore
    Vellore, Tamil Nadu 632 004, India
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Schneider Children's Medical Center
    Petah Tiqva, 4920235, Israel
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • ASST Spedali Civili - Università degli Studi
    Brescia, 25123, Italy
  • Ospedale SS. Annunziata
    Chieti, 66100, Italy
  • Azienda Ospedaliero Universitaria Meyer
    Firenze, 50139, Italy
  • Ospedale Pediatrico Gaslini - Istituto Giannina Gaslini
    Genova, 16147, Italy
  • Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
    Milano, 20122, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • Ospedale Infantile Burlo Garofolo
    Trieste, 34137, Italy
  • Kanazawa University Hospital
    Kanazawa, Ishikawa 920 8641, Japan
  • Kanagawa Children's Medical Center
    Yokohama, Kanagawa 232-8555, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 236-0004, Japan
  • Miyagi Children's Hospital
    Sendai, Miyagi 989-3126, Japan
  • Osaka Medical & Pharma Univ Hp
    Takatsuki, Osaka 569-8686, Japan
  • Saitama Children's Medical Center
    Saitama-shi, Saitama 330 8777, Japan
  • Tokyo Medical And Dental University Medical Hospital
    Bunkyō, Tokyo 113-8519, Japan
  • St. Lukes International Hospital
    Chuo-Ku, Tokyo 104 8560, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Kagoshima University Hospital
    Kagoshima, 890-8520, Japan
  • Niigata University Medical & Dental Hospital
    Niigata, 951-8520, Japan
  • Clinstile, S.A. de C.V.
    Cuauhtemoc, Federal District 06700, Mexico
  • CREA de Guadalajara, S.C.
    Guadalajara, Jalisco 44620, Mexico
  • Hospital Univ. "Dr. José Eleuterio González"
    Monterrey, Nuevo León 64460, Mexico
  • Investigacion y Biomedicina de Chihuahua
    Chihuahua, 31000, Mexico
  • Instituto de Investigaciones Aplicadas a la Neurociencia A.C
    Durango, 34000, Mexico
  • Wojewódzki Specjalistyczny Szpital Dziecięcy im. św. Ludwika w Krakowie
    Krakow, 31-503, Poland
  • CSK, Uniwersyteckie Centrum Pediatrii im.M.Konopnickiej,Klinika Kardiologii i Reumatologii Dzieciecej
    Lodz, 91-738, Poland
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
    Warszawa, 02-637, Poland
  • V.A. Nasonova Research Institute of Rheumatology
    Moscow, 115522, Russian Federation
  • Morozovsky Children's City Clinical Hospital
    Moscow, 119049, Russian Federation
  • First Moscow State Medical University n.a. Sechenov
    Moscow, 119991, Russian Federation
  • Scientific Center of Children's Health
    Moscow, 119991, Russian Federation
  • Saint-Petersburg State Pediatric Medical University
    Saint Petersburg, 194100, Russian Federation
  • Hospital Sant Joan de Deu
    Barcelona, Cataluna 08950, Spain
  • Complexo Hospitalario Universitario A Coruña, CHUAC
    La Coruña, 15006, Spain
  • Hospital Infantil Universitario Niño Jesús
    Madrid, 28009, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario La Fe de Valencia
    Valencia, 46026, Spain
  • Istanbul University Cerrahpasa Medical Faculty
    Istanbul, 34098, Turkey
  • Dokuz Eylul University Hospital
    Izmir, 35340, Turkey
  • University College Hospital - London
    London, Greater London W1T 7HA, United Kingdom
  • Great Ormond Street Hospital For Children NHS Foundation Trust
    Bloomsbury, London WC1N 3JH, United Kingdom
  • Sheffield Children's Hospital
    Sheffield, South Yorkshire S10 2TH, United Kingdom
  • Bristol Royal Hospital for Children
    Bristol, BS2 8BJ, United Kingdom
  • Alder Hey Children's NHS Foundation Trust
    Liverpool, L14 5AB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Jan 2022, 37 months.

Results were first posted in Oct 2022, 8 months after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 37 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2018
First posted
Dec 12, 2018
StartActual
Dec 17, 2018
Primary completionActual
Jan 26, 2022
CompletionActual
Jan 26, 2022
Results first posted
Oct 7, 2022
Last update
Oct 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03773978
Responsible party
Sponsor
First posted
Dec 12, 2018
Start date
Dec 17, 2018
Primary completion
Jan 26, 2022
Completion
Jan 26, 2022
Results posted
Oct 7, 2022
Last update
Oct 7, 2022

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion